Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Certification to Accompany Drug, Biological Product, and Device Applications or Submissions, 75819-75820 [2014-29752]

Download as PDF Federal Register / Vol. 79, No. 244 / Friday, December 19, 2014 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2008–N–0144] Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Certification to Accompany Drug, Biological Product, and Device Applications or Submissions AGENCY: Food and Drug Administration, HHS. ACTION: Notice. The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995. DATES: Fax written comments on the collection of information by January 20, 2015. ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, FAX: 202–395–7285, or emailed to oira_ submission@omb.eop.gov. All comments should be identified with the OMB control number 0910–0616. Also include the FDA docket number found in brackets in the heading of this document. SUMMARY: FDA PRA Staff, Office of Operations, Food and Drug Administration, 8455 Colesville Rd., COLE–14526, Silver Spring, MD 20993–0002, PRAStaff@fda. hhs.gov. SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance. FOR FURTHER INFORMATION CONTACT: mstockstill on DSK4VPTVN1PROD with NOTICES Certification To Accompany Drug, Biological Product, and Device Applications or Submissions (Form FDA 3674)—(OMB Control Number 0910–0616)—Extension The information required under section 402(j)(5)(B) of the Public Health Service Act (PHS Act) (42 U.S.C. 282(j)(5)(B)) is submitted in the form of a certification, Form FDA 3674, which accompanies applications and submissions currently submitted to FDA and is already approved by OMB. The OMB control numbers and expiration dates for submitting FDA 3674 under VerDate Sep<11>2014 19:37 Dec 18, 2014 Jkt 235001 the following parts are: 21 CFR parts 312 and 314 (human drugs) are 0910– 0014, expiring April 30, 2015, and 0910–0001, expiring September 30, 2014; 21 CFR parts 312 and 601 (biological products) are 0910–0014 and 0910–0338, expiring January 31, 2017; 21 CFR parts 807 and 814 (devices) are 0910–0120, expiring January 31, 2017, and 0910–0231, expiring January 31, 2017. Title VIII of the Food and Drug Administration Amendments Act of 2007 (Pub. L. 110–85) amended the PHS Act by adding section 402(j). The provisions require additional information to be submitted to the clinical trials data bank, http://www. clinicaltrials.gov/ (FDA has verified the Web site address, but FDA is not responsible for any subsequent changes to the Web site after this document publishes in the Federal Register), previously established by the National Institutes of Health/National Library of Medicine, including expanded information on clinical trials and information on the results of clinical trials. The provisions include responsibilities for FDA as well as several amendments to the Federal Food, Drug, and Cosmetic Act (the FD&C Act). One provision, section 402(j)(5)(B) of the PHS Act, requires that a certification accompany human drug, biological, and device product submissions made to FDA. Specifically, at the time of submission of an application under sections 505, 515, or 520(m) of the FD&C Act (21 U.S.C. 355, 360e, or 360j(m)), or under section 351 of the PHS Act (42 U.S.C. 262), or submission of a report under section 510(k) of the FD&C Act (21 U.S.C. 360(k)), such application or submission must be accompanied by a certification, Form FDA 3674, that all applicable requirements of section 402(j) of the PHS Act have been met. Where available, such certification must include the appropriate National Clinical Trial (NCT) numbers. The proposed extension of the collection of information is necessary to satisfy the previously mentioned statutory requirement. The importance of obtaining these data relates to adherence to the legal requirements for submissions to the clinical trials registry and results data bank and ensuring that individuals and organizations submitting applications or reports to FDA under the listed provisions of the FD&C Act or the PHS Act adhere to the appropriate legal and regulatory requirements for certifying to having complied with those requirements. The failure to submit the certification PO 00000 Frm 00036 Fmt 4703 Sfmt 4703 75819 required by section 402(j)(5)(B) of the PHS Act, and the knowing submission of a false certification are both prohibited acts under section 301 of the FD&C Act (21 U.S.C. 331). Violations are subject to civil money penalties. In January 2009, FDA issued ‘‘Guidance for Sponsors, Industry, Researchers, Investigators, and Food and Drug Administration Staff— Certifications to Accompany Drug, Biological Product, and Device Applications/Submissions: Compliance With Section 402(j) of The Public Health Service Act, Added By Title VIII of the Food and Drug Administration Amendments Act of 2007’’ available at http://www.fda.gov/regulatory Information/guidances/ucm125335.htm. This guidance identified the applications and submissions that FDA considered should be accompanied by the certification form, Form FDA 3674. The applications and submissions noted in the guidance are reflected in the burden analysis. Investigational New Drug Applications FDA’s Center for Drug Evaluation and Research (CDER) received 1,564 investigational new drug applications (INDs) and 14,328 clinical protocol IND amendments in calendar year (CY) 2013. CDER anticipates that IND and clinical protocol amendment submission rates will remain at or near this level in the near future. FDA’s Center for Biologics Evaluation and Research (CBER) received 451 new INDs and 492 clinical protocol IND amendments in CY 2013. CBER anticipates that IND and clinical protocol amendment submission rates will remain at or near this level in the near future. The estimated total number of submissions (new INDs and new protocol submissions) subject to mandatory certification requirements under section 402(j)(5)(B) of the PHS Act, is 15,892 for CDER plus 943 for CBER, or 16,835 submissions per year. The minutes per response is the estimated number of minutes that a respondent would spend preparing the information to be submitted to FDA under section 402(j)(5)(B) of the PHS Act, including the time it takes to enter the necessary information on the form. Based on its experience with current submissions, FDA estimates that approximately 15 minutes on average would be needed per response for certifications which accompany IND applications and clinical protocol amendment submissions. It is assumed that most submissions to investigational applications will reference only a few protocols for which the sponsor/ applicant/submitter has obtained a NCT E:\FR\FM\19DEN1.SGM 19DEN1 75820 Federal Register / Vol. 79, No. 244 / Friday, December 19, 2014 / Notices number from http://www.clinical trials.gov/ prior to making the submission to FDA. It is also assumed that the sponsor/applicant/submitter has electronic capabilities allowing them to retrieve the information necessary to complete the form in an efficient manner. Marketing Applications/Submissions In CY 2013, CDER and CBER received 226 new drug applications (NDA)/ biologics license applications (BLA)/ resubmissions and 932 NDA/BLA amendments for which certifications are needed. CDER and CBER received 198 efficacy supplements/resubmissions to previously approved NDAs/BLAs in CY 2013. CDER and CBER anticipate that new drug/biologic applications/ resubmissions and efficacy supplement submission rates will remain at or near this level in the near future. FDA’s Center for Devices and Radiological Health (CDRH) received a total of 530 new applications for premarket approvals (PMA), 510(k) submissions containing clinical information, PMA supplements, applications for humanitarian device exemptions (HDE) and amendments in CY 2013. CDRH anticipates that application, amendment, supplement, and annual report submission rates will remain at or near this level in the near future. FDA’s Office of Generic Drugs (OGD) received 1,001 abbreviated new drug applications (ANDAs) in 2013. OGD received 989 bioequivalence amendments/supplements in 2013. OGD anticipates that application, amendment, and supplement submission rates will remain at or near this level in the near future. Based on its experience reviewing NDAs, BLAs, PMAs, HDEs, 510(k)s, and ANDAs and experience with current submissions of Form FDA 3674, FDA estimates that approximately 45 minutes on average would be needed per response for certifications which accompany NDA, BLA, PMA, HDE, 510(k), and ANDA marketing applications and submissions. It is assumed that the sponsor/applicant/ submitter has electronic capabilities allowing them to retrieve the information necessary to complete the form in an efficient manner. In the Federal Register of July 9, 2014 (79 FR 38905), FDA published a 60-day notice requesting public comment on the proposed collection of information. We received no comments. FDA estimates the burden of this collection of information as follows: TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1 Number of respondents (investigational applications) FDA center activity Number of respondents (marketing applications) Number of responses per respondent Total annual responses Average burden per response Total hours CDER New Applications (IND) .................. Clinical Protocol Amendments (IND). New Marketing Applications/Resubmissions (NDA/BLA). Clinical Amendments to Marketing Applications. Efficacy Supplements/Resubmissions. 1,564 14,328 ........................ ........................ 1 1 1,546 14,328 0.25 (15 minutes) .... 0.25 (15 minutes) .... 387 3,582 ........................ 191 1 191 0.75 (45 minutes) .... 143 ........................ 932 1 932 0.75 (45 minutes) .... 699 ........................ 173 1 173 0.75 (45 minutes) .... 130 CBER New Applications (IND) .................. Clinical Protocol Amendments (IND). New Marketing Applications/Resubmissions (NDA/BLA). Clinical Amendments to Marketing Applications. Efficacy Supplements/Resubmissions (BLA only). 451 492 ........................ ........................ 1 1 451 492 0.25 (15 minutes) .... 0.25 (15 minutes) .... 113 123 ........................ 35 1 35 0.75 (45 minutes) .... 26 ........................ 0 1 0 0.75 (45 minutes) .... 1 ........................ 25 1 25 0.75 (45 minutes) .... 19 1 530 0.75 (45 minutes) .... 398 CDRH New Marketing Applications (includes PMAs, HDEs, Supplements and 510(k)s expected to contain clinical data). ........................ 530 OGD Original Applications ...................... BE Supplements/Amendments ...... ........................ ........................ 1,001 989 1 1 1,001 989 0.75 (45 minutes) .... 0.75 (45 minutes) .... 751 742 Total ........................................ ........................ ........................ ........................ ........................ ................................. 7,114 mstockstill on DSK4VPTVN1PROD with NOTICES 1 There are no capital costs or operating and maintenance costs associated with this collection of information. Dated: December 15, 2014. Leslie Kux, Associate Commissioner for Policy. [FR Doc. 2014–29752 Filed 12–18–14; 8:45 am] BILLING CODE 4164–01–P VerDate Sep<11>2014 19:37 Dec 18, 2014 Jkt 235001 PO 00000 Frm 00037 Fmt 4703 Sfmt 9990 E:\FR\FM\19DEN1.SGM 19DEN1

Agencies

[Federal Register Volume 79, Number 244 (Friday, December 19, 2014)]
[Notices]
[Pages 75819-75820]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-29752]



[[Page 75819]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2008-N-0144]


Agency Information Collection Activities; Submission for Office 
of Management and Budget Review; Comment Request; Certification to 
Accompany Drug, Biological Product, and Device Applications or 
Submissions

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing that a 
proposed collection of information has been submitted to the Office of 
Management and Budget (OMB) for review and clearance under the 
Paperwork Reduction Act of 1995.

DATES: Fax written comments on the collection of information by January 
20, 2015.

ADDRESSES: To ensure that comments on the information collection are 
received, OMB recommends that written comments be faxed to the Office 
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, 
FAX: 202-395-7285, or emailed to oira_submission@omb.eop.gov. All 
comments should be identified with the OMB control number 0910-0616. 
Also include the FDA docket number found in brackets in the heading of 
this document.

FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations, 
Food and Drug Administration, 8455 Colesville Rd., COLE-14526, Silver 
Spring, MD 20993-0002, PRAStaff@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has 
submitted the following proposed collection of information to OMB for 
review and clearance.

Certification To Accompany Drug, Biological Product, and Device 
Applications or Submissions (Form FDA 3674)--(OMB Control Number 0910-
0616)--Extension

    The information required under section 402(j)(5)(B) of the Public 
Health Service Act (PHS Act) (42 U.S.C. 282(j)(5)(B)) is submitted in 
the form of a certification, Form FDA 3674, which accompanies 
applications and submissions currently submitted to FDA and is already 
approved by OMB. The OMB control numbers and expiration dates for 
submitting FDA 3674 under the following parts are: 21 CFR parts 312 and 
314 (human drugs) are 0910-0014, expiring April 30, 2015, and 0910-
0001, expiring September 30, 2014; 21 CFR parts 312 and 601 (biological 
products) are 0910-0014 and 0910-0338, expiring January 31, 2017; 21 
CFR parts 807 and 814 (devices) are 0910-0120, expiring January 31, 
2017, and 0910-0231, expiring January 31, 2017.
    Title VIII of the Food and Drug Administration Amendments Act of 
2007 (Pub. L. 110-85) amended the PHS Act by adding section 402(j). The 
provisions require additional information to be submitted to the 
clinical trials data bank, http://www.clinicaltrials.gov/ (FDA has 
verified the Web site address, but FDA is not responsible for any 
subsequent changes to the Web site after this document publishes in the 
Federal Register), previously established by the National Institutes of 
Health/National Library of Medicine, including expanded information on 
clinical trials and information on the results of clinical trials. The 
provisions include responsibilities for FDA as well as several 
amendments to the Federal Food, Drug, and Cosmetic Act (the FD&C Act).
    One provision, section 402(j)(5)(B) of the PHS Act, requires that a 
certification accompany human drug, biological, and device product 
submissions made to FDA. Specifically, at the time of submission of an 
application under sections 505, 515, or 520(m) of the FD&C Act (21 
U.S.C. 355, 360e, or 360j(m)), or under section 351 of the PHS Act (42 
U.S.C. 262), or submission of a report under section 510(k) of the FD&C 
Act (21 U.S.C. 360(k)), such application or submission must be 
accompanied by a certification, Form FDA 3674, that all applicable 
requirements of section 402(j) of the PHS Act have been met. Where 
available, such certification must include the appropriate National 
Clinical Trial (NCT) numbers.
    The proposed extension of the collection of information is 
necessary to satisfy the previously mentioned statutory requirement. 
The importance of obtaining these data relates to adherence to the 
legal requirements for submissions to the clinical trials registry and 
results data bank and ensuring that individuals and organizations 
submitting applications or reports to FDA under the listed provisions 
of the FD&C Act or the PHS Act adhere to the appropriate legal and 
regulatory requirements for certifying to having complied with those 
requirements. The failure to submit the certification required by 
section 402(j)(5)(B) of the PHS Act, and the knowing submission of a 
false certification are both prohibited acts under section 301 of the 
FD&C Act (21 U.S.C. 331). Violations are subject to civil money 
penalties.
    In January 2009, FDA issued ``Guidance for Sponsors, Industry, 
Researchers, Investigators, and Food and Drug Administration Staff--
Certifications to Accompany Drug, Biological Product, and Device 
Applications/Submissions: Compliance With Section 402(j) of The Public 
Health Service Act, Added By Title VIII of the Food and Drug 
Administration Amendments Act of 2007'' available at http://www.fda.gov/regulatoryInformation/guidances/ucm125335.htm. This 
guidance identified the applications and submissions that FDA 
considered should be accompanied by the certification form, Form FDA 
3674. The applications and submissions noted in the guidance are 
reflected in the burden analysis.

Investigational New Drug Applications

    FDA's Center for Drug Evaluation and Research (CDER) received 1,564 
investigational new drug applications (INDs) and 14,328 clinical 
protocol IND amendments in calendar year (CY) 2013. CDER anticipates 
that IND and clinical protocol amendment submission rates will remain 
at or near this level in the near future.
    FDA's Center for Biologics Evaluation and Research (CBER) received 
451 new INDs and 492 clinical protocol IND amendments in CY 2013. CBER 
anticipates that IND and clinical protocol amendment submission rates 
will remain at or near this level in the near future. The estimated 
total number of submissions (new INDs and new protocol submissions) 
subject to mandatory certification requirements under section 
402(j)(5)(B) of the PHS Act, is 15,892 for CDER plus 943 for CBER, or 
16,835 submissions per year. The minutes per response is the estimated 
number of minutes that a respondent would spend preparing the 
information to be submitted to FDA under section 402(j)(5)(B) of the 
PHS Act, including the time it takes to enter the necessary information 
on the form.
    Based on its experience with current submissions, FDA estimates 
that approximately 15 minutes on average would be needed per response 
for certifications which accompany IND applications and clinical 
protocol amendment submissions. It is assumed that most submissions to 
investigational applications will reference only a few protocols for 
which the sponsor/applicant/submitter has obtained a NCT

[[Page 75820]]

number from http://www.clinicaltrials.gov/ prior to making the 
submission to FDA. It is also assumed that the sponsor/applicant/
submitter has electronic capabilities allowing them to retrieve the 
information necessary to complete the form in an efficient manner.

Marketing Applications/Submissions

    In CY 2013, CDER and CBER received 226 new drug applications (NDA)/
biologics license applications (BLA)/resubmissions and 932 NDA/BLA 
amendments for which certifications are needed. CDER and CBER received 
198 efficacy supplements/resubmissions to previously approved NDAs/BLAs 
in CY 2013. CDER and CBER anticipate that new drug/biologic 
applications/resubmissions and efficacy supplement submission rates 
will remain at or near this level in the near future.
    FDA's Center for Devices and Radiological Health (CDRH) received a 
total of 530 new applications for premarket approvals (PMA), 510(k) 
submissions containing clinical information, PMA supplements, 
applications for humanitarian device exemptions (HDE) and amendments in 
CY 2013. CDRH anticipates that application, amendment, supplement, and 
annual report submission rates will remain at or near this level in the 
near future.
    FDA's Office of Generic Drugs (OGD) received 1,001 abbreviated new 
drug applications (ANDAs) in 2013. OGD received 989 bioequivalence 
amendments/supplements in 2013. OGD anticipates that application, 
amendment, and supplement submission rates will remain at or near this 
level in the near future.
    Based on its experience reviewing NDAs, BLAs, PMAs, HDEs, 510(k)s, 
and ANDAs and experience with current submissions of Form FDA 3674, FDA 
estimates that approximately 45 minutes on average would be needed per 
response for certifications which accompany NDA, BLA, PMA, HDE, 510(k), 
and ANDA marketing applications and submissions. It is assumed that the 
sponsor/applicant/submitter has electronic capabilities allowing them 
to retrieve the information necessary to complete the form in an 
efficient manner.
    In the Federal Register of July 9, 2014 (79 FR 38905), FDA 
published a 60-day notice requesting public comment on the proposed 
collection of information. We received no comments.
    FDA estimates the burden of this collection of information as 
follows:

                                                     Table 1--Estimated Annual Reporting Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
                                          Number of        Number of
                                         respondents      respondents      Number of     Total annual
         FDA center activity          (investigational    (marketing     responses per     responses       Average burden per response      Total hours
                                        applications)    applications)    respondent
--------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                          CDER
--------------------------------------------------------------------------------------------------------------------------------------------------------
New Applications (IND)..............            1,564   ..............               1           1,546  0.25 (15 minutes)...............             387
Clinical Protocol Amendments (IND)..           14,328   ..............               1          14,328  0.25 (15 minutes)...............           3,582
New Marketing Applications/           ................             191               1             191  0.75 (45 minutes)...............             143
 Resubmissions (NDA/BLA).
Clinical Amendments to Marketing      ................             932               1             932  0.75 (45 minutes)...............             699
 Applications.
Efficacy Supplements/Resubmissions..  ................             173               1             173  0.75 (45 minutes)...............             130
--------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                          CBER
--------------------------------------------------------------------------------------------------------------------------------------------------------
New Applications (IND)..............              451   ..............               1             451  0.25 (15 minutes)...............             113
Clinical Protocol Amendments (IND)..              492   ..............               1             492  0.25 (15 minutes)...............             123
New Marketing Applications/           ................              35               1              35  0.75 (45 minutes)...............              26
 Resubmissions (NDA/BLA).
Clinical Amendments to Marketing      ................               0               1               0  0.75 (45 minutes)...............               1
 Applications.
Efficacy Supplements/Resubmissions    ................              25               1              25  0.75 (45 minutes)...............              19
 (BLA only).
--------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                          CDRH
--------------------------------------------------------------------------------------------------------------------------------------------------------
New Marketing Applications (includes  ................             530               1             530  0.75 (45 minutes)...............             398
 PMAs, HDEs, Supplements and 510(k)s
 expected to contain clinical data).
--------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                           OGD
--------------------------------------------------------------------------------------------------------------------------------------------------------
Original Applications...............  ................           1,001               1           1,001  0.75 (45 minutes)...............             751
BE Supplements/Amendments...........  ................             989               1             989  0.75 (45 minutes)...............             742
                                     -------------------------------------------------------------------------------------------------------------------
    Total...........................  ................  ..............  ..............  ..............  ................................           7,114
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.


    Dated: December 15, 2014.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2014-29752 Filed 12-18-14; 8:45 am]
BILLING CODE 4164-01-P